Development of a new class of alkali activated binders for producing low-carbon concrete

开发用于生产低碳混凝土的新型碱活化粘合剂

基本信息

  • 批准号:
    577059-2022
  • 负责人:
  • 金额:
    $ 25.5万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Alliance Grants
  • 财政年份:
    2022
  • 资助国家:
    加拿大
  • 起止时间:
    2022-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

The cement and concrete industry accounts for ~ 8% of global anthropogenic greenhouse gas (GHG) emissions every year. That is mainly due to the reliance on the consumption of Portland cement to form the binder. A practical solution to cut such large emissions is to use alternative binders. Alkali activated binders (AABs) are among alternative binders that have received a lot of attention recently. They have been commercially used in various construction projects in several countries such as the United Kingdom and Australia. In their classic form, AABs are formed by adding an alkaline material such as sodium hydroxide to an aluminosilicate powder such as metakaolin. Industrial by-products such as fly ash and slag have also been successfully used at a commercial scale as precursors for the production of the AABs with lower cost and carbon footprint. Although AABs have great potentials to reduce the GHG emissions associated with the concrete industry, there have been limited research and development activities on such binders for Canadian construction applications. Moreover, typical precursors, such as fly ash and slag, are now in limited supply, particularly in Western Canada. Here, we propose to use a natural pozzolan, which is rich in zeolites and basalts and is largely available in British Columbia (BC), as the precursor for developing a new class of AABs. Moreover, we will tailor the properties of these new binders by adding to them relatively small amounts of our in-house prepared naturally-derived nanoparticles. By conducting performance-based comparative life cycle assessments, we will also quantify the effects of the new binders on the GHG emission reduction. We have partnered with ZMM® Canada Minerals Corporation, a BC-based zeolite mining company. This partnership, in addition to the collaboration with a team of members from academia and Innovate Calgary, the university's technology transfer office, will promote the impact of our proposed research program and support the translation activities and commercialization of this new technology. This research program will also train a diverse group of HQP in applications of materials engineering and nanotechnology for the concrete industry.
水泥和混凝土行业每年约占全球人为温室气体(GHG)排放量的8%。这主要是因为依赖波特兰水泥的消费来形成粘结剂。减少如此大的排放量的一个实际解决方案是使用替代粘结剂。碱激活粘结剂(AABS)是近年来备受关注的替代粘结剂之一。它们已经在英国和澳大利亚等几个国家的各种建筑项目中进行了商业使用。在它们的经典形式中,AABS是通过向偏高岭土等铝硅酸盐粉末中添加碱性材料(如氢氧化钠)而形成的。工业副产品,如飞灰和炉渣,也已成功地在商业规模上用作生产成本较低和碳足迹较低的AABS的前体。尽管AABS在减少与混凝土行业相关的温室气体排放方面具有巨大的潜力,但针对加拿大建筑应用的此类粘结剂的研究和开发活动有限。此外,典型的前体,如飞灰和矿渣,现在供应有限,特别是在加拿大西部。在这里,我们建议使用一种天然火山灰,这种火山灰富含沸石和玄武岩,主要存在于不列颠哥伦比亚省(BC),作为开发新类别AABS的先驱。此外,我们将通过向这些新粘合剂中添加相对少量的我们内部制备的自然衍生纳米颗粒来调整它们的性能。通过进行以性能为基础的生命周期比较评估,我们还将量化新粘结剂对温室气体减排的影响。我们与不列颠哥伦比亚省沸石开采公司ZMM®Canada Minerals Corporation建立了合作伙伴关系。除了与学术界和创新卡尔加里大学技术转移办公室的成员合作外,这一合作伙伴关系还将促进我们拟议的研究计划的影响,并支持这项新技术的翻译活动和商业化。该研究计划还将培训不同的HQP在混凝土行业的材料工程和纳米技术应用方面的培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Khoshnazar, RahilR其他文献

Khoshnazar, RahilR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Khoshnazar, RahilR', 18)}}的其他基金

Development of eco-friendly silicate-based nanoparticles for sustainable concrete infrastructure
开发用于可持续混凝土基础设施的环保硅酸盐基纳米颗粒
  • 批准号:
    570366-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Alliance Grants

相似国自然基金

脊髓新鉴定SNAPR神经元相关环路介导SCS电刺激抑制恶性瘙痒
  • 批准号:
    82371478
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
tau轻子衰变与新物理模型唯象研究
  • 批准号:
    11005033
  • 批准年份:
    2010
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
HIV gp41的NHR区新靶点的确证及高效干预
  • 批准号:
    81072676
  • 批准年份:
    2010
  • 资助金额:
    33.0 万元
  • 项目类别:
    面上项目
强子对撞机上新物理信号的多轻子末态研究
  • 批准号:
    10675110
  • 批准年份:
    2006
  • 资助金额:
    36.0 万元
  • 项目类别:
    面上项目

相似海外基金

Development of a new class of BLVRB-targeted redox therapeutics in breast cancer
开发一类新型 BLVRB 靶向乳腺癌氧化还原疗法
  • 批准号:
    10759653
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes
开发类视黄醇途径的一流拮抗剂作为 2 型糖尿病的新型口服疗法
  • 批准号:
    10699637
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Development of First-in-Class PDE5/HAT Directed LigandsModulating Molecular Pathways involved in Synaptic Plasticity
开发一流的 PDE5/HAT 定向配体调节参与突触可塑性的分子途径
  • 批准号:
    10654103
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers
开发类视黄醇途径的一流拮抗剂作为实体癌的新型口服免疫疗法
  • 批准号:
    10604218
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Enabling Older Adults to 'LiveWell' with Advanced Heart Failure: Development of a Palliative Rehabilitation Model
让患有晚期心力衰竭的老年人“活得更好”:姑息康复模型的开发
  • 批准号:
    10663457
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
PFI-TT: Development of A New Class of Low-Power, Plasma-Based Wind Turbine Icing Protection Systems
PFI-TT:开发新型低功率等离子体风力涡轮机结冰保护系统
  • 批准号:
    2140489
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Standard Grant
Development of a New Class of Broad-Stage Antimalarial Agents
新型多阶段抗疟药物的开发
  • 批准号:
    nhmrc : 2000087
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Development Grants
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer
转移性乳腺癌一流疗法的临床开发
  • 批准号:
    10253272
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
一流的 ETS 抑制剂 TK216:转化生物学和口服剂型开发
  • 批准号:
    10259473
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer
转移性乳腺癌一流疗法的临床开发
  • 批准号:
    10596292
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了